Constitutively Active Death Receptor (CADRE) for Cancer Treatment ID: 2021-034

CADRE is a groundbreaking innovation designed to induce apoptosis in cancer cells without the need for external activation, offering a novel approach to cancer treatment.

Technology Overview

The technology involves a mutation in the transmembrane domain of the Fas receptor to create a Constitutively Active Death Receptor (CADRE) that triggers cell apoptosis autonomously. This receptor functions without the external ligands typically required for cell death, making it a potent anti-cancer agent that can initiate the death of cancerous cells while minimizing inflammation.

Key Advantages

• Induces apoptosis without external activation, simplifying the process of targeting cancer cells
• Minimizes inflammatory responses compared to necrosis, reducing potential side effects
• Demonstrates broad efficacy across multiple cancer cell lines, suggesting wide applicability
• Compatible with various delivery systems, including liposomes and viral vectors, offering flexibility in treatment approaches

Problems Addressed

• Reduces reliance on external ligands for apoptosis, addressing a major limitation in targeted cancer therapies
• Decreases the inflammatory response associated with cancer treatment, improving patient comfort and outcomes
• Offers a solution to the cardiotoxicity and systemic side effects of traditional chemotherapeutic agents
• Provides a more targeted approach to apoptosis, potentially increasing the specificity and efficacy of cancer treatment

Additional Information

Technology ID: 2022-002
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025